Abstract
1. Six subjects participated in a detailed pharmacokinetic study of tolbutamide (pilot study). Using parameters based on these data, sixty-three non-diabetic volunteers underwent a simple screening test designed to identify slow metabolisers of tolbutamide. 2. The screening test was an estimate of tolbutamide plasma elimination half-life from plasma concentrations at 8 and 24 h after 500 mg tolbutamide orally, and urinary recovery of the hydroxy- and carboxytolbutamide metabolites over the 4-8 h post-dose period. 3. The mean tolbutamide half-life for 61 of the screened subjects was 7.5 +/- 1.5 h (range 5.2-12.2 h). Two subjects had half-lives of 21.6 and 16.1 h. Their urinary metabolite recoveries were within the range of those in the screening test but lower than those in the pilot study. 4. The subject with the 21.6 h half-life was restudied with intensive serial sampling for 72 h post-dose. She was confirmed as a 'slow' metaboliser of tolbutamide since her terminal half-life was 25.9 h but plasma Cmax and tmax were within the range of those in the detailed study. This subject's 24 h urinary recoveries of both hydroxytolbutamide and carboxytolbutamide were clearly different from the mean values for the pilot study subjects implicating hydroxylation of tolbutamide as the metabolic defect. 5. The two point plasma half-life is therefore a discriminatory screening test but a 4-8 h urinary recovery is not. 6. A partial family study did not provide conclusive evidence of the inheritance of slow tolbutamide metabolism but the screening test should allow simple identification of slow metabolisers for further study.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Back D. J., Tjia J., Mönig H., Ohnhaus E. E., Park B. K. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157–163. doi: 10.1007/BF00614553. [DOI] [PubMed] [Google Scholar]
- Brian W. R., Srivastava P. K., Umbenhauer D. R., Lloyd R. S., Guengerich F. P. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry. 1989 Jun 13;28(12):4993–4999. doi: 10.1021/bi00438a014. [DOI] [PubMed] [Google Scholar]
- Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988 Feb 4;331(6155):442–446. doi: 10.1038/331442a0. [DOI] [PubMed] [Google Scholar]
- Jackson P. R., Tucker G. T., Lennard M. S., Woods H. F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol. 1986 Nov;22(5):541–550. doi: 10.1111/j.1365-2125.1986.tb02933.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knodell R. G., Hall S. D., Wilkinson G. R., Guengerich F. P. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther. 1987 Jun;241(3):1112–1119. [PubMed] [Google Scholar]
- Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26(6):753–759. doi: 10.1007/BF00541938. [DOI] [PubMed] [Google Scholar]
- Melander A., Sartor G., Wåhlin E., Scherstén B., Bitzén P. O. Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus. Br Med J. 1978 Jan 21;1(6106):142–144. doi: 10.1136/bmj.1.6106.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miners J. O., Foenander T., Wanwimolruk S., Gallus A. S., Birkett D. J. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur J Clin Pharmacol. 1982;22(4):321–326. doi: 10.1007/BF00548400. [DOI] [PubMed] [Google Scholar]
- Miners J. O., Wing L. M., Birkett D. J. Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. Aust N Z J Med. 1985 Jun;15(3):348–349. doi: 10.1111/j.1445-5994.1985.tb04052.x. [DOI] [PubMed] [Google Scholar]
- Nebert D. W., Nelson D. R., Adesnik M., Coon M. J., Estabrook R. W., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Kemper B. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA. 1989 Jan-Feb;8(1):1–13. doi: 10.1089/dna.1.1989.8.1. [DOI] [PubMed] [Google Scholar]
- Peart G. F., Boutagy J., Shenfield G. M. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. Eur J Clin Pharmacol. 1987;33(4):397–402. doi: 10.1007/BF00637637. [DOI] [PubMed] [Google Scholar]
- Relling M. V., Aoyama T., Gonzalez F. J., Meyer U. A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther. 1990 Jan;252(1):442–447. [PubMed] [Google Scholar]
- Scott J., Poffenbarger P. L. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes. 1979 Jan;28(1):41–51. [PubMed] [Google Scholar]
- Shibasaki J., Konishi R., Morishita T., Ueki T. Drug absorption, metabolism, and excretion. IX. Some new aspects of pharmacokinetics on tolbutamide in rabbits. Chem Pharm Bull (Tokyo) 1973 Aug;21(8):1754–1763. doi: 10.1248/cpb.21.1754. [DOI] [PubMed] [Google Scholar]
- Veronese M. E., Miners J. O., Randles D., Gregov D., Birkett D. J. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther. 1990 Mar;47(3):403–411. doi: 10.1038/clpt.1990.46. [DOI] [PubMed] [Google Scholar]